We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

70 hedge funds and large institutions have $34M invested in Theriva Biologics in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 9

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

17% more funds holding

Funds holding: 60 → 70 (+10)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

44% less capital invested

Capital invested by funds: $60.8M → $34M (-$26.8M)

Holders
70
Holders Change
+10
Holders Change %
+16.67%
% of All Funds
1.75%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
20
Increased
21
Reduced
9
Closed
9
Calls
$7.97M
Puts
–
Net Calls
+$7.97M
Net Calls Change
+$7.97M

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$5.38M
2
SM
Sabby Management
Florida
+$3.56M
3
MP
MSD Partners
New York
+$1.18M
4
UOC
UBS O'Connor
Illinois
+$1.17M
5
Millennium Management
Millennium Management
New York
+$883K

Top Sellers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
-$1.99M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$1.14M
3
William Blair & Company
William Blair & Company
Illinois
-$411K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$131K
5
RCP
Rothschild Capital Partners
New York
-$52K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$128K +$195K +19 New
IA
27
IFP Advisors
Florida
$125K – – –
Fisher Asset Management
28
Fisher Asset Management
Washington
$102K +$92.4K +9 +150%
FSA
29
Franklin Street Advisors
North Carolina
$96K – – –
TA
30
Teachers Advisors
New York
$92K – – –
Charles Schwab
31
Charles Schwab
California
$91K – – –
Creative Planning
32
Creative Planning
Kansas
$82K +$61.6K +6 +100%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$77K – – –
SBIA
34
Sheaff Brock Investment Advisors
Indiana
$76K +$10.3K +1 +10%
SAM
35
Scopus Asset Management
New York
$76K +$113K +11 New
Citigroup
36
Citigroup
New York
$75K +$103K +10 +1,000%
BA
37
Bard Associates
Illinois
$67K -$10.3K -1 -9%
LTFS
38
Ladenburg Thalmann Financial Services
Florida
$67K – – –
Deutsche Bank
39
Deutsche Bank
Germany
$65K +$92.4K +9 +900%
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$46K -$20.5K -2 -22%
NFA
41
Nationwide Fund Advisors
Ohio
$36K – – –
Squarepoint
42
Squarepoint
New York
$35K +$51.3K +5 New
AIG
43
American International Group
New York
$33K – – –
BA
44
BlackRock Advisors
Delaware
$33K – – –
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
$33K – – –
HighTower Advisors
46
HighTower Advisors
Illinois
$29K -$10.3K -1 -20%
VOYA Investment Management
47
VOYA Investment Management
Georgia
$29K – – –
CS
48
Credit Suisse
Switzerland
$29K +$10.3K +1 +33%
Wells Fargo
49
Wells Fargo
California
$27K – – –
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$26K – – –
1
2
3 4

TOVX Hedge Fund Activity: Q4 2016 in Review

70 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2016, worth a combined $34M — down 44% from $60.8M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new TOVX positions and 9 closed out — a net gain of 11 holders — while 21 added to existing stakes and 9 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $5.38M. The largest seller was Knoll Capital Management, cutting an estimated $1.99M.

  • 70 institutional investors held Theriva Biologics (TOVX) as of Q4 2016, up from 60 in Q3 2016.
  • Funds reported $34M of Theriva Biologics stock for Q4 2016, down 44% quarter-over-quarter.
  • 20 funds opened new Theriva Biologics positions in Q4 2016 and 9 closed out, a net change of +11 holders.
  • The largest Theriva Biologics buyer in Q4 2016 was Alyeska Investment Group, an estimated $5.38M added.
  • The largest Theriva Biologics seller in Q4 2016 was Knoll Capital Management, an estimated $1.99M sold.

Based on aggregated 13F filings for Q4 2016.